Meanwhile, the S&P/ASX All Ordinaries Index (ASX: XAO) has risen 4% in the YTD and is also 10% higher over the past year.

The interest rate-cutting cycle that has begun in the US, Australia, and many other nations is a tailwind for ASX small-cap shares.

This is because small-caps are typically young companies carrying more debt than larger companies to fund their early growth.

In this article, we reveal 3 ASX small-cap shares that have caught the eye of analysts.

Experts give buy ratings to 3 ASX small-cap shares

Arthur Garipoli of Seneca Financial Solutions has a buy rating on the following two ASX small-cap shares.

MTM Critical Metals (ASX: MTM)

MTM Critical Minerals is an e-scrap recycling company that extracts metal, such as gold, copper and tin, from discarded electronics.

Garipoli says this ASX small-cap share is more suited to higher-risk investors.

He explains this buy rating (courtesy The Bull):

MTM's flash joule heating technology is proven, with commercial production targeted for 2026.

The company has locked in two supply agreements totalling 1100 tonnes per annum of e-scrap.

MTM recently secured firm commitments to raise $50 million from institutional investors.

The company may re-rate on potential catalysts that include offtake agreements and completing the demonstration plant.

The MTM Critical Metals share price is up 175% in the YTD and up an astounding 1,687% over the past 12 months.

XRF Scientific (ASX: XRF)

XRF Scientific is a service provider in the mining industry. It makes equipment and chemicals used in preparing samples for analysis.

Garipoli says this ASX small-cap share remains "under the radar" due to its market capitalisation (which is $258 million).

He comments:

XRF holds a strong competitive position and operates a recurring revenue business model.

The company has generated profit growth in the past five years.

A weaker share price followed a 9 per cent fall in revenue in the March quarter of fiscal year 2025 when compared to the prior corresponding period.

However, profit before tax rose 5 per cent, creating a buying opportunity, in our view.

The XRF Scientific share price is down 8% in the YTD and up 31% over the past 12 months.

But wait, there's more…

Stuart Bromley of Medallion Financial Group has been watching another ASX small-cap share that he considers promising.

Southern Cross Electrical Engineering (ASX: SXE)

Southern Cross Electrical Engineering provides electrical, instrumentation, security, fire, communications, and maintenance services.

The company recently bought Force Fire Holdings for an initial payment of $36.3 million and a total consideration of $53.5 million.

Southern Cross Electrical Engineering funded the purchase with its cash reserves.

Bromley told The Bull:

The acquisition will enhance the company's service offerings in the fire safety space.

The project pipeline remains strong after recently announcing it had been awarded projects of $70 million, including the Western Sydney Airport stand-alone facilities project and a hyperscale data centre, also in Western Sydney.

Southern Cross Electrical Engineering shares are up 16% in the YTD and up 6% over the past 12 months.

The post Hidden gems: Experts name 3 ASX small-cap shares to buy now appeared first on The Motley Fool Australia.

After all, every other investor is also well acquainted with all those names that are familiar to you, so there are really no secrets or bargains.

But those more obscure businesses that are not often discussed could be going for cheap with plenty of future potential.

Medallion Financial Group advisor Stuart Bromley recently named two such ASX shares that are his picks for 2024:

Appealing for customers seeking 'the best available solution'

Biotech stock Polynovo Ltd (ASX: PNV) is down more than 31.5% over the past 12 months, but the burns recovery solutions provider is on the cusp of exiting the pre-revenue phase.

"PolyNovo's innovative products are competitively priced and are often significantly cheaper than competitors in major markets," Bromley told The Bull.

"Consequently, the company's products and pricing power appeals to hospitals searching for the best available solution."

Polynovo's $66.5 million revenue in the 2023 financial year was up almost 60%, which is appealing for Bromley.

"The company continues to expand geographically, which generates new revenue streams."

The income is invested back into the business for its future pipeline, giving investors excellent hope for growth.

"The company's investment in products and staff should reward investors moving forward," said Bromley.

"In our view, the company offers a bright outlook in fiscal year 2024 and beyond."

Selling consumables to famous clients

XRF Scientific Limited (ASX: XRF) is a $160 million small-cap that makes products for testing mineral samples.

Bromley loves its long list of big-name customers.

"XRF's blue-chip clients highlight the quality of its offering, with the company servicing Rio Tinto Ltd (ASX: RIO), BHP Group Ltd (ASX: BHP), Vale SA (NYSE: VALE), South32 Ltd (ASX: S32), Glencore PLC (LON: GLEN) and Alcoa Corp (NYSE: AA), among others."

After an up-and-down 12 months, the XRF share price is now trading more than 35% higher.

Sales revenue, net profit and operating cash flow were all up substantially in the 2023 financial year.

Bromley tells investors to not be fooled by XRF Scientific's small size, as the business is "fundamentally strong".

"We're optimistic given the company generated revenue of $13.6 million in the 2023 September quarter, up 8% on the prior corresponding period. 

"The company generated $5.1 million in capital equipment product sales, up from $4 million in the prior corresponding period."

And there is a huge ace up the sleeve for those willing to invest for the long run.

"We expect the forward-looking investor will also benefit from higher margin recurring revenues anticipated to flow through from the consumables side of the business, in the form of chemicals and labware required for ongoing sample analysis."

The post 'Bright outlook': 2 ASX shares ready for a massive 2024 you've not thought about appeared first on The Motley Fool Australia.

Well, if you want to chase that feeling, here are three buy suggestions from the experts:

'Increased focus on profitability'

Perhaps no stock has frustrated investors in recent years as much as Tyro Payments Ltd (ASX: TYR).

The fintech showed so much potential upon listing in late 2019, but the business dealt with one setback after another since — some self-inflicted, some external.

The share price is now almost 70% down on its September 2021 peak.

However, Sequoia Wealth Management senior wealth manager Peter Day reckons green shoots started to appear during reporting season.

"The company generated EBITDA of $42.3 million in fiscal year 2023, up 297% year-on-year," Day told The Bull.

"Transaction value of $42.6 billion was up 25%."

Indeed, some of the market has taken notice, with Tyro shares heading 17.3% up since 28 August.

With the company changing its priorities in recent times, Day thinks there's plenty more where that came from.

"The increased focus on profitability has continued to drive upgrades. 

"We're mindful of potential macroeconomic headwinds, but the risks appear skewed to the upside based on the recent performance across Tyro's core verticals."

Pumping up the dividends

Medallion Financial Group private client advisor Stuart Bromley's pick is XRF Scientific Limited (ASX: XRF).

The stock is 17.4% trading lower since the start of August, perhaps opening up a nice buying window.

The business' fortunes are linked to the commodities market.

"XRF makes equipment and chemicals used in preparing samples for analysis for the mining industry," said Bromley.

There were plenty of growth shoots from the recent results.

"The company reported sales revenue of $55.2 million in fiscal year 2023, up 38% on the prior corresponding period. 

"The capital equipment division lifted sales revenue by 75%, which we expect to supercharge the recurring revenue consumables arm in the future. The business continues to deliver increasing dividends."

Indeed, XRF pays out a dividend yield of 2.8%.

'Resilient and defensive earnings'

Are rising interest rates and cost-of-living pressures driving you to the drink?

If enough Australians are feeling the same, Endeavour Group Ltd (ASX: EDV) might do well in the near future.

That's at least what Seneca Financial Solutions investment advisor Tony Langford thinks, as he's rating the stock a buy.

"The operator of liquor outlets Dan Murphy's and BWS provides resilient and defensive earnings in an increasingly challenging consumer environment," he said.

"The hotels business has recovered from disruptions caused by the pandemic."

The signs from last month's reporting season were positive.

"Group sales of $11.9 billion in fiscal year 2023 were up 2.5% on the prior corresponding period. Group net profit after tax up of $529 million was up 6.9%. 

"The full year dividend of 21.8 cents a share was up 7.9%."

The post 'Supercharge recurring revenue': 3 ASX shares to buy before everyone else wakes up appeared first on The Motley Fool Australia.

Banks are nervous that the liquidity spotlight will turn to them, investors are nervous about further interest rate rises, and consumers are nervous about recession and unemployment.

It's an anxious time for all concerned.

That's why stock picking is now more fraught than ever. So it's not a bad idea to avoid being too cute and buy ASX shares of businesses that are already exhibiting positive signs.

Here are two such examples from Medallion Financial Group director Philippe Bui:

'Strong tailwinds heading into fiscal year 2024'

The XRF Scientific Limited (ASX: XRF) has already rocketed 18.6% year to date, but Bui feels like the climb isn't finished yet.

"Recent half year results from this equipment and chemicals manufacturer were impressive," Bui told The Bull.

"Sales revenue of $27.1 million was up 46% on the prior corresponding period. Net profit after tax of $3.7 million was up 34%."

The industrial testing and chemical goods provider has a bright outlook.

"The capital equipment part of the business seems to have strong tailwinds heading into fiscal year 2024."

Despite an almost 55% climb over the past year, Bui is not worried that XRF shares have already exhausted their run. 

"Despite share price strength, the business was recently trading on a reasonable price-earnings multiple of 18 times."

Market yet to price in guidance upgrade

Insurance repairer Johns Lyng Group Ltd (ASX: JLG) seems to be popular among professional investors at the moment.

According to CMC Markets, incredibly all 10 analysts that follow the stock are currently rating it as a strong buy.

Bui is no different.

"First half 2023 group sales revenue of $635.6 million was up 71.2% on the prior corresponding period."

He noted the company forecast an upgrade to its 2023 revenue by 11.2% for fiscal year 2023. 

"We believe the market is yet to fully price in the significant uptick to full year guidance," said Bui.

"Work volumes in the next six months may surprise to the upside."

Johns Lyng stock price has gained 5.8% so far this year. But it may still be a buying opportunity as it's still more than 26.8% lower than where it was 12 months ago.

The post 'Surprise to upside': 2 ASX shares to buy now for future growth appeared first on The Motley Fool Australia.

Writing in its October 2022 monthly report, the 1851 Emerging Companies Fund says it has seen "some of the largest daily movements in our index for many years".

"In over 15 years of investing in the Australian small-cap sector, we have never seen the fast-changing macroeconomic environment driving share price moves like we are witnessing as opposed to underlying company fundamentals."

Managed by small-cap veteran Chris Stott, since inception in February 2020 the 1851 Emerging Companies Fund has returned 12.8% per annum, soundly outperforming its benchmark.

October saw the fund rise 4.4% after fees compared to its benchmark's rise of 6.5%

Contributors to performance included the XRF Scientific Limited (ASX: XRF) share price jumping 24% higher for the month after the manufacturer of equipment and chemicals largely for the mining sector reported a "strong trading period across all divisions, driven by activity in the mining sector and buoyant demand for capital equipment products".

On the flip side, the Eureka Group Holdings Ltd (ASX: EGH) share price fell 14% in October after the owner and manager of senior independent living communities announced a $28m capital raise at $0.47 to fund the purchase of two new villages. The company also announced they are in due diligence with over $20m worth of further potential acquisitions. 

In early November, 1851 Capital lodged a notice of initial substantial holder with the ASX, declaring it held 5.06% voting power in Eureka Group. 

The fund's five largest positions are listed as Capitol Health Ltd (ASX: CAJ), PSC Insurance Group Ltd (ASX: PSI), PeopleIn Ltd (ASX: PPE), OFX Group Ltd (ASX: OFX) and Ridley Corporation Ltd (ASX: RIC).

The OFX Group share price continued its upward trajectory into November after the foreign exchange services company reported a strong performance for the first half of FY23, including upgrading its profit guidance for the full year. In what has been a tough year for many payment companies, OFX Group shares have been a standout, gaining 57% over the past 12 months.

1851 Capital expects inflation to peak this coming quarter, saying the impact of the recent east coast rain will likely drive food prices higher once again. Despite the recent hikes in interest rates, the fund says economic activity continues to remain robust with no major slowdown evident.

"We continue researching for companies to position for an inevitable economic recovery over the medium term," concluded the fund.

The post Top fund manager has 'never seen' ASX share price moves like we are witnessing appeared first on The Motley Fool Australia.

If you're just holding large-cap household names, then you might as well just put your money into an index fund, they say.

Smaller businesses also present more opportunities when the stock price doesn't fairly reflect the actual future potential, or even current performance.

The fewer people that pay attention to it, the higher the chance the share price will peel off what's expected.

With this in mind, here are a pair of ASX shares you may not have heard of that experts have picked as "buys" right now:

'Earnings outlook is strong'

In a year when most ASX shares have dipped, the NRW Holdings Limited (ASX: NWH) stock price has risen more than 20%.

"The earnings outlook is strong for this mining services company," Fairmont Equities founder Michael Gable told The Bull.

The company provides contracted services to the mining industry. Think drilling, digging, blasting and equipment maintenance.

NWR is riding the boom that its resources sector clients are currently experiencing.

Despite the recent share price surge, Gable feels like "the valuation remains cheap". 

"From a charting perspective, the share price had been consolidating for the past few months before breaking higher after its half-year results," he said.

"We now expect the shares to trend higher from here."

'Strong tailwinds'

XRF Scientific Limited (ASX: XRF) also services the mining industry but with more scientific activities, such as chemical analysis.

According to Medallion Financial Group director Philippe Bui, the company put up "solid results" for the first half.

"Revenue grew by 24% and net profit after tax increased by 17%," he said. 

"Also, results indicated continuing momentum into the second half, with record orders."

With the resources sector basking in increasing commodity prices, Bui sees more upward movement for the XRF Scientific share price.

"Increasing capital expenditure is expected in the mining exploration sector, which should provide strong tailwinds for XRF."

The share price more than quadrupled since the March 2020 COVID-19 crash.

Bui's colleague Michael Wayne told The Motley Fool last year that XRF's valuation was still not excessive.

"It's got a strong balance sheet," he said. 

"A multiple of 25, 30 times earnings, as well, isn't too challenging for a company that is growing quite nicely."

The post 2 totally obscure ASX shares in the buy zone right now: experts appeared first on The Motley Fool Australia.

The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. Yesterday, Medallion Financial managing director Michael Wayne revealed the 3 ASX shares that have gone gangbusters for him. Today, he explains why he's getting his clients to buy 3 ASX shares in particular.

Hottest ASX shares

The Motley Fool: What are the 3 best stock buys right now?

Michael Wayne: One that we've been buying consistently really over the last couple of years with some degree of success has been Audinate Group Ltd (ASX: AD8). 

We continue to like this company, particularly as we emerge from lockdown. Audinate's involved in the audio digital space. It essentially allows different pieces of electronic equipment to communicate without the needs for cords and cables. So if you think about a Bose sound system, or Toshiba, all these different brands effectively embed this protocol that Audinate creates called Dante. 

And about 80% of new products coming to market incorporate this Dante product. So they've got a pretty strong market position. The adoption rate of their technology is about 18 times the nearest competitor. They're also now moving into the visual-digital space as well, so that would be a new market for them. 

Obviously COVID wasn't great for them, because if you think about outdoor concerts or large sporting events, they were on the backburner. But we're now coming out of that, and this is a company that should benefit from that.

One caveat — and they have been under a little bit of pressure recently, although they're starting to bounce back now — is that they are having some supply issues, like many other businesses across numerous industries at the moment, which is making it a bit difficult for them to meet their demand. But the good thing is their order backlog is very, very juicy, and it's growing very, very quickly. So as long as they can continue to meet that demand, they should be in a pretty good position.

MF: This is a long term investment?

MW: Yeah. I mean, long term as long as something can be long term. Obviously, we're reviewing the updates and the annual reports and half-year reports, et cetera, but we would like to see this one as a long term hold for sure. 

The balance sheet's improving a lot. They've spent a lot on research and development in recent years and that's starting to come to fruition for them. So we see no reason why this can't be an unregulated monopoly of sorts… So yeah, we think it's a long term buy.

Second one on the list is a company called XRF Scientific Limited (ASX: XRF). 

Although it is a smaller company, it's not trading on the lofty multiples that you would normally associate with the tech space. 

XRF Scientific's effectively a mining services company. They sell machines to mining companies so that they can conduct tests on their core samples. And what's good about that is not only do they sell the machines, they then sell them the chemicals which are used in those tests, and the chemicals are consumable in nature. So once they're used once, they've got to be replenished and bought again.

It's a good recurring revenue stream for them. They've obviously been benefitting from the boom that we've been seeing across most commodity suites at the moment. 

Pays a good solid dividend yearly, about 3.5%. It's got a strong balance sheet. They too have spent a lot on research and development in recent years and that's started to pay off for them. A multiple of 25, 30 times earnings, as well, isn't too challenging for a company that is growing quite nicely.

MF: Its clients are mining companies, so are there any worries about their cyclical nature?

MW: Look, that is definitely one element of concern, being in the mining space. They do have applications for other industries as well. But the fact is they are growing quickly enough too, we think, offsets any sustained downturn in the mining space. 

That's definitely something you've got to be conscious of. But we're pretty confident that the commodities space will hold up. I mean, commodities are very, very cyclical, as you say, and almost impossible to predict, but looking across the board, not just at your typical iron ore and coal, et cetera, but some of these newer type commodities that are emerging and becoming more and more prevalent, we think will support that going forward.

MF: And the third one?

MW: The third one, I'm going to go a bit more boring here. Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) is one that we have been buying for clients in the last couple of days, for those that don't already hold it, and for some clients even topping up. 

They had a very good update. Obviously, being in the respiratory and acute care, they've been benefiting from the COVID situation. But much of the market was predicting that that COVID boost would fade, but as it turns out, although the numbers have come back a little bit, their results delivered far in excess of expectations across the market. 

We think that that COVID story, as we're seeing in Europe and Africa, won't necessarily disappear overnight, and is going to be a lot more sustained than people originally thought, so we think that Fisher & Paykel will continue to benefit from that.

They're also seeing some good sales outside of the typical markets of US and Europe, which we think bodes well for future growth drivers, those emerging markets. There have been some strong signs in their nasal high flow therapy adoption as well, which we think is promising for them. 

Also, Fisher & Paykel [has] one of the highest quality balance sheets on the market, and at the moment, it is trading on a PE multiple at the bottom end of its long term average.

We think it's not a bad time to be looking to pick up a very good quality growth business at a multiple that is very challenging by traditional metrics, but for this business, it's on the lower end of that scale. For a company that's growing as quickly as they are, they can very quickly justify and grow into that multiple.

The post 3 hot ASX shares to buy right now: advisor appeared first on The Motley Fool Australia.

Therefore it is wise to see if there are any stocks that might have big news coming up.

Medallion Financial managing director Michael Wayne this week picked out for his clients a trio of ASX shares to watch.

He told The Motley Fool these businesses are worth picking up for investors willing to put up with "a little pre-report risk".

"We feel these 3 are a good chance of delivering and continuing the good momentum they've been displaying in recent months."

Don't let the decline in revenue fool you

Wayne is intrigued by debt buyer Credit Corp Group Limited (ASX: CCP) this reporting season.

"Management have shown themselves to be very adept at purchasing wisely, building solid debt ledgers over an extended period of time," he said in a report to clients.

"We are optimistic that this careful approach, which served them well through the GFC, can drive growth into the future and we are supportive of a strong board which has worked closely with management to restore value for shareholders after the initial COVID-19 falls."

Credit Corp shares closed Wednesday at $27.74, which is down almost 10% for the year.

The company revealed its half-year revenues declined. But Wayne suggested not overplaying this.

"While revenues fell by 2% to $188 million, the key for a business like Credit Corp is their profitability as it indicates how well they're selecting and how efficiently they're recovering the debt they purchase," he said.

"In this instance, net profit after tax grew at a strong 10% to… $42.3 million against the prior corresponding half."

The share price has dipped almost 6% in the past month and, according to Wayne, this presents an entry opportunity.

"With no alarming issues raised in the business update, a growing US presence and strong management track record, we see this week's approximate $1.30 pull-back as an opportune time to consider Credit Corp."

Small-cap ASX share with solid financials

Wayne reckons while scientific laboratory equipment provider XRF Scientific Limited (ASX: XRF) doesn't have a huge market cap, it has a reliable history.

"We believe this to be a great business which exhibits solid financials over an extended period," he said.

"XRF has delivered consistent growth in key metrics and after confirming a 47% increase in net profit to $2.4 million for the first half of FY21 in February and an impressive March quarter more recently, we are confident of continued growth being delivered in their upcoming full year results to be delivered in August."

XRF is due to report its financials to the market on 24 August.

Its share price is up almost 47% for the year, to close Wednesday at 44 cents. It has cooled off in the past month though, dropping more than 6%.

Wayne said there's a little icing on top for those willing to back the business.

"XRF also pays an approximate 2.9% fully franked dividend."

'Unregulated monopoly' for this Aussie business

Audinate Group Ltd (ASX: AD8)'s flagship product Dante allows audio equipment to communicate with each other via computer networking cables.

It's a business that Wayne has vouched for previously.

"They're growing very, very quickly. The adoption rate… is about 17 times the nearest competitor," he told The Motley Fool back in May.

"I think about 75% of new audio equipment and digital equipment incorporates the Audinate Dante protocol. And that should mean that they're embedded into that industry for some time to come."

The stock advisor still has the same conviction ahead of the August reporting season.

"At this stage the business is still building scale — but at this rapid rate of progression, it is conceivable in our view that the Dante product will emerge as an unregulated monopoly," he said this week.

"This is particularly positive news with market data forecasting the networked audio space is expected to triple from 2020 to 2024."

Audinate shares are up more than 14% for the year, closing Wednesday at $9.42. Its preliminary report is due 19 August.

The post 3 intriguing ASX shares to buy before reporting season appeared first on The Motley Fool Australia.

At the time of writing, the XRF Scientific share price is trading 13.79% higher to 33 cents.

XRF Scientific report details

The March quarter delivered solid results for the company. Given XRF manufactures and sells predominantly precious metal equipment/instruments, it's not all too surprising to see the company faring well.

XRF Scientific's unaudited results show $8.2 million in revenue for the recent quarter. This is an increase of 20% compared to the $6.9 million for the same period last year. The elevated revenue inflated the company's profits with profit before tax growing 81% to $1.8 million.

With mining companies ramping up sample testing, XRF's consumable product sales performed strongly, coming in at $2.67 million. Additionally, XRF's sales of capital equipment were reported to be robust – currently with an order book of two months' worth of sales.

Furthermore, precious metal sales experienced a strong quarter with platinum labware being in high demand. On that front, XRF Scientific's Germany office has been expanding market share, while maintaining profitability throughout the entire March quarter.

Looking forward

In further news boosting the XRF Scientific share price, the company highlighted its future quarter outlook, saying:

Based on the current level of activity we expect the June 2021 quarter to generate a strong result. During this upcoming quarter, we are continuing with expansion activities such as new product development, M&A opportunities and increasing our precious metals customer base in Europe. 

XRF Scientific share price shines

For a company with a small market capitalisation, at $39 million, the XRF Scientific share price has been delivering solid returns of late. In the last year, shares have rallied 94% to their highest level since 2013.

This didn't come so easy for long-term shareholders though. Prior to these substantial gain, XRF shares fell 37% during the COVID-19 crash.

The post XRF Scientific (ASX:XRF) share price soars 14% on revenue growth appeared first on The Motley Fool Australia.

A quick guide to ASX dividends

When building a sustainable portfolio of ASX dividend shares, investors need to focus on three things. First, there is no need to look only at the top 20 or 50 companies. A company has to have a proven, cash-generating business model. Second, you must be able to invest in ASX dividend shares without sacrificing your capital. Third, a company should be able to pay the dividends from direct earnings. 

So let's take a look at my pick of 4 high yield ASX dividend shares to buy right now.

Southern Cross Electrical Engineer Ltd (ASX: SXE)

Southern Cross is an electrical contracting company. I worked on several construction projects for the company more than 20 years ago. This share goes ex-dividend on 7 October, 2020. At today's closing price, the payment will be a yield of 6.12%. In addition, this ASX dividend share has paid a consistent dividend in 8 of the past 10 years. In the past 3 years, the Southern Cross share price has fallen after payment, but has regained ground again. The company already has $330 million of secured project work in FY21, which accounts for 80% of the revenue target.

XRF Scientific Limited (ASX: XRF)

XRF is a small cap company that manufactures equipment and chemicals used in the preparation of samples for analysis. To illustrate the value of this company, in FY20 it increased its net profit after tax (NPAT) by 46%. This ASX dividend share goes ex-dividend on 1 October with a payment that will yield 4.59% based on today's closing price. Based in Perth, the company is keyed into the mining industry and has a diverse range of mining clients. 

GR Engineering Services Ltd (ASX: GNG)

GR Engineering provides engineering design, procurement and construction services to the mining and mineral processing industry and the provision of operations, maintenance, projects and advisory services to the oil and gas sector. It forecasts revenue for FY21 to be in the range of $280 million to $300 million, with improvement in margins.

This ASX dividend share goes ex-dividend on 8 October with a payment that will yield 3.96% based on today's closing price.

Harvey Norman Holdings Limited (ASX: HVN) 

Harvey Norman has had a great year during the pandemic. In fact, NPAT rose by 19.4% compared to FY19 due to the work from home phenomenon, and an increase in online sales. The Harvey Norman ASX dividend payment will yield 3.93% at today's closing price. The ex-dividend date is 9 October.

The post 4 high yield ASX dividend shares to buy right now appeared first on The Motley Fool Australia.